对阿尔茨海默病生物学定义的挑战
Jemma Hazan1, Kathy Y Liu1, Harry Costello1
1From the University College London (J.H., K.Y.L., H.C., R.H.); Neuroscience & Cell Biology Research Institute (J.D.I.), St George's, University of London, United Kingdom; and Clinical and Translational Neuroscience Section (M.T.), National Institutes of Health, Bethesda, MD; Laboratory of Behavioral Neuroscience (M.T.), National Institute on Aging, Baltimore, MD.
Neurology
|October 1, 2024
概括
修订后的阿尔茨海默病 (AD) 标准建议使用像粉样蛋白和蛋白这样的生物标志物来诊断AD,而无需临床症状. 虽然提供了更清晰的定义,但纯生物学方法需要进一步验证和考虑其他生物标志物.
科学领域:
- 神经学 神经学
- 生物标志物发现发现
- 阿尔茨海默病的诊断方法 诊断方法
背景情况:
- 阿尔茨海默病 (AD) 的诊断正在转向基于生物标志物的方法.
- 最近FDA对粉样蛋白降低治疗的批准正在推动这一转变.
- 修订后的标准建议仅基于生物标志物,独立于临床症状的AD诊断.
研究的目的:
- 探索转向基于生物标志物的AD诊断背后的驱动因素.
- 评估阿尔茨海默病诊断和分期的拟议修订标准.
- 考虑使用这些新标准的支持和反对的论点.
主要方法:
- 基于粉样蛋白和蛋白生物标志物的AD诊断提出的标准的审查.
- 使用PET成像,CSF和等离子体生物标记物的诊断方法的分析.
- 评估纯粹基于生物标志物的诊断框架的优点和局限性.
主要成果:
- 拟议的标准允许通过使用各种生物标志物通过粉样蛋白或酸化阳性来诊断AD.
- 一个潜在的好处是对AD的更清晰的定义,将神经病理与临床综合征区分开来.
- 担忧包括纯粹生物定义的类别错误的风险以及对纵向数据的需求.
结论:
- 纯粹生物学定义的AD可能会产生类别错误;需要纵向数据来评估生物标志物阳性个体的痴呆风险.
- 限制生物标志物范围仅限于粉样蛋白和陶是值得谨慎的.
- 目前的标准应该留在研究中,但等离子体生物标志物需要考虑临床实践.
相关概念视频
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Dementia
99
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
99
Biological Causes of Schizophrenia
47
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
47
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Parkinson's Disease: Overview
492
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
492


